The monthlong US government shutdown is forcing some companies to seek alternate routes to go public while the main markets regulator is unable to greenlight IPOs.

Biotechnology companies Gossamer Bio and TCR2 Therapeutics have been exploring a little-used workaround that would let them begin trading without the usual Securities and Exchange Commission signoff, according to people familiar with the matter.